Przejdź do zawartości
Merck
  • The effect of gabapentin versus intrathecal fentanyl on postoperative pain and morphine consumption in cesarean delivery: a prospective, randomized, double-blind study.

The effect of gabapentin versus intrathecal fentanyl on postoperative pain and morphine consumption in cesarean delivery: a prospective, randomized, double-blind study.

Archives of gynecology and obstetrics (2014-02-13)
Abdolreza Najafi Anaraki, Kamran Mirzaei
ABSTRAKT

Pain after cesarean delivery is a leading cause of chronic pain and there are many attempts to reduce it without total success. Gabapentin is effective in reducing acute and chronic pain with little experience in parturient. The purpose of this study is to compare the effect of pre-emptive gabapentin with intrathecal fentanyl on reducing postoperative pain and morphine consumption in cesarean surgery. Seventy-eight primiparous women who scheduled for non-emergency cesarean delivery were enrolled in the study and separated into two groups. The control group received 12.5 mg of heavy bupivacaine 0.5 % plus 10 μg of fentanyl intrathecally and the case group received 300 mg of gabapentin orally 2 h before surgery and 12.5 mg of heavy bupivacaine 0.5 % intrathecally. Data collection including blood pressure, heart rate, neonate sedation, Apgar score, visual analogous scale at several hours, at first, need to analgesic postoperatively. In the fentanyl group, the need for analgesic drug was earlier, total dose of morphine in 24 h and patient satisfaction was higher than the gabapentin group. The mean visual analogous scale at several hours postoperatively in the fentanyl groups was significantly higher than the gabapentin groups (P = 0.001). Preemptive use of gabapentin is a safe and effective way to reduce postoperative pain and morphine consumption in parturients after cesarean surgery.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
γ-Aminobutyric acid, ≥99%
Supelco
Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
γ-Aminobutyric acid, analytical standard
Supelco
Morphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Fentanyl solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Fentanyl solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
γ-Aminobutyric acid, BioXtra, ≥99%
Vigabatrin impurity D, European Pharmacopoeia (EP) Reference Standard
Morphine sulfate, European Pharmacopoeia (EP) Reference Standard
USP
Gabapentin, United States Pharmacopeia (USP) Reference Standard
Supelco
Gabapentin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Gabapentyna Związek pokrewny A, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Gabapentin, solid
Supelco
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard
Bupivacaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Morphine for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Gabapentin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®